Drugs / recombinant human porphobilinogen deaminase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00418795 | Jun 2003 → Jun 2006 | acute intermittent porphyria | Zymenex A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human porphobilinogen deaminase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00418795 ↗ |
| Known as | Porphozym | “Porphozym (recombinant human porphobilinogen deaminase)in the treatment of acute attacks in AIP.” NCT00418795 ↗ |
| Modality | Protein / enzyme biologic | “Porphozym (recombinant human porphobilinogen deaminase)” NCT00418795 ↗ |
| Route | Intravenous | “continuous iv infusion of the enzyme over the following 48 hours.” NCT00418795 ↗ |